251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
22<br />
The BioTech Region Munich-Martinsried<br />
Prompted by its victory in the 1996 Bio-Regio Competition organised by the Federal Ministry of Education and Research,<br />
the Munich BioTech Region has developed into one of the leading clusters within Europe. Today, Munich leads Germany as<br />
regards the number of companies, employees and, most of all, the number of drugs in clinical development.<br />
Especially in the field of therapeutics and diagnostics, the region has become Germany's most important location.<br />
The central network coordinator for this cluster is BioM <strong>Biotech</strong> Cluster Development GmbH.<br />
The Munich BioTech Region: an international reputation, successful<br />
companies, a strong medical drugs pipeline<br />
The well-functioning network of science, industry and<br />
politics provides the biotechnology companies with a<br />
decisive locational advantage that has enabled the Munich<br />
BioTech Region to develop into Germany's leading biotechnology<br />
cluster. With more than 190 companies and more<br />
than 13,000 employees in the Life Science sector, and with<br />
two universities (which just recently joined the ranks of<br />
Germany's elite universities), two universities of applied<br />
sciences, the Max Plank Institutes of Biochemistry, Neurobiology<br />
and Psychiatry, the Helmholtz Research Center for<br />
Environmental Health, as well as further renowned institutes<br />
and organizations, the region offers an outstanding environ-<br />
Martinsried<br />
ment for innovations. The small and medium-sized biotechnology<br />
companies focus on so-called “red biotechnology”,<br />
especially on research and development in the field of<br />
diagnostics and therapeutics. Small and medium sized<br />
enterprises (SMEs) from Munich are at the very forefront of<br />
drug development throughout Germany – two products<br />
from MediGene have received marketing approval, further<br />
products have already been approved in other countries and<br />
are expected to receive approval in Germany in 2008. Eight<br />
companies are listed on the stock exchange, among them<br />
MorphoSys, one of the region's largest companies and one<br />
of those with the highest turnover.